BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
2808627
Number of visits today
393
Number of downloads
2060627
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Tamir H, Melamed S, Erez N, Politi B, Yahalom-ronen Y, Achdout H, Lazar S, Gutman H, Avraham R, Weiss S, Paran N, Israely T. Induction of Innate Immune Response by TLR3 Agonist Protects Mice against SARS-CoV-2 Infection. Viruses 2022;14:189. [DOI: 10.3390/v14020189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Farkas D, Bogamuwa S, Piper B, Newcomb G, Gunturu P, Bednash JS, Londino JD, Elhance A, Nho R, Mejia OR, Yount JS, Horowitz JC, Goncharova EA, Mallampalli RK, Robinson RT, Farkas L. A role for Toll-like receptor 3 in lung vascular remodeling associated with SARS-CoV-2 infection. bioRxiv 2023:2023. [PMID: 36747676 DOI: 10.1101/2023.01.25.524586] [Reference Citation Analysis]
2 Karki R, Kanneganti TD. Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J Transl Med 2022;20:542. [PMID: 36419185 DOI: 10.1186/s12967-022-03767-z] [Reference Citation Analysis]
3 Balkrishna A, Goswami S, Singh H, Gohel V, Dev R, Haldar S, Varshney A. Herbo-mineral formulation, Divya-Swasari-Vati averts SARS-CoV-2 pseudovirus entry into human alveolar epithelial cells by interfering with spike protein-ACE 2 interaction and IL-6/TNF-α /NF-κB signaling. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1024830] [Reference Citation Analysis]
4 Liu Z, Yang M, Yu K, Lian Z, Deng S. Toll-like receptor (TLRs) agonists and antagonists for COVID-19 treatments. Front Pharmacol 2022;13:989664. [DOI: 10.3389/fphar.2022.989664] [Reference Citation Analysis]
5 Farooq M, Khan AW, Ahmad B, Kim MS, Choi S. Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection. Front Pharmacol 2022;13:915565. [DOI: 10.3389/fphar.2022.915565] [Reference Citation Analysis]
6 Tiwari S, Goel G, Kumar A. Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19. Int Rev Immunol 2022;:1-20. [PMID: 35757923 DOI: 10.1080/08830185.2022.2089666] [Reference Citation Analysis]
7 Sagulkoo P, Suratanee A, Plaimas K. Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing. Biomolecules 2022;12:690. [DOI: 10.3390/biom12050690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345